Impact News +++ Bitfarms Shareholders Approve U.S. Redomiciliation Plan (GlobeNewswire EN) +++ BITFARMS Aktie +3,37%

INOVIO Aktie

>INOVIO Aktienkurs

1.4 EUR -2.1% (TradegateBSX)

Ask: 1.42 EUR / 2098 Stück

Bid: 1.37 EUR / 2198 Stück

Tagesumsatz: 212 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

INOVIO Aktie über LYNX handeln

Intraday

1 Jahr

>INOVIO Performance

1 Woche: -3,4%

1 Monat: 0%

3 Monate: -30,7%

6 Monate: -28,2%

1 Jahr: -24,3%

laufendes Jahr: -5,4%

>INOVIO Aktie

Name:

INOVIO PHARMACEUTICAL INC

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US45773H4092 / A400EJ

Symbol/ Ticker:

GBM (Frankfurt) / INO (NASDAQ)

Kürzel:

FRA:GBM, ETR:GBM, GBM:GR, NASDAQ:INO

Index:

Webseite:

https://inovio.com/

Profil:

Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing DNA medicines for treating and protecting against HPV-related diseases, cancer, and i..
>Volltext..

Marktkapitalisierung:

99.06 Mio. EUR

Unternehmenswert:

57.64 Mio. EUR

Umsatz:

0.06 Mio. EUR

EBITDA:

-72.41 Mio. EUR

Nettogewinn:

-73.37 Mio. EUR

Gewinn je Aktie:

-1.67 EUR

Schulden:

8.09 Mio. EUR

Liquide Mittel:

38.24 Mio. EUR

Operativer Cashflow:

-76.55 Mio. EUR

Bargeldquote:

1.34

Umsatzwachstum:

-73.55%

Gewinnwachstum:

30.19%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

INOVIO

Letzte Datenerhebung:

21.03.26

>INOVIO Kennzahlen

Aktien/ Unternehmen:

Aktien: 69.09 Mio. St.

Frei handelbar: 99.58%

Leerverk. Aktien: 15.86%

Rückkaufquote: -46.35%

Mitarbeiter: 112

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 303.92%

Bewertung:

KGV: -

KGV lG: -

KUV: 1742.74

KBV: 4.74

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -4474.06%

Gewinnmarge: -130000%

Operative Marge: -132871.32%

Managementeffizenz:

Gesamtkaprendite: -89.14%

Eigenkaprendite: -183.47%

>INOVIO Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>INOVIO Chart & Kurs - NASDAQ

>INOVIO News

18.03.26 - 23:15	INO Deadline: INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 18, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026......

17.03.26 - 21:27	INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to......

17.03.26 - 21:00	Inovio (INO) Q4 2025 Earnings Call Transcript (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

16.03.26 - 21:27	Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, March 16, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). IF YOU SUFFERED A LOSS ON......

13.03.26 - 02:57	Inovio targets October 30 PDUFA date for INO-3107 approval while extending cash runway into Q4 2026 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.03.26 - 23:43	Inovio Pharmaceuticals: Kostensenkungen führen zu Quartalsgewinn und verlängerter finanzieller Reichweite (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

12.03.26 - 21:36	Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, March 12, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR......

12.03.26 - 21:09	INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (PR Newswire)
	Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA)......

12.03.26 - 15:06	Pomerantz Law Firm Announces the Filing of a Class Action Against Inovio Pharmaceuticals, Inc. and Certain Officers - INO (PR Newswire)
	NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO) and certain officers.   The class action, filed in the United States District Court for the Eastern......

11.03.26 - 21:48	Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	BENSALEM, Pa., March 11, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). IF YOU ARE......

11.03.26 - 14:21	INO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals (INO) Investors of Securities Class Action Deadline on April 7, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to......

10.03.26 - 22:01	Inovio auf Life-Sciences-Konferenz: Strategische Einblicke zum Hoffnungsträger INO-3107 (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

09.03.26 - 13:06	INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
	PLYMOUTH MEETING, Pa., March 9, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate......

06.03.26 - 15:51	INO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Pharmaceuticals Investors of Securities Class Action Deadline on April 7, 2026 (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Inovio To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to......

05.03.26 - 22:09	INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 (PR Newswire)
	PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its fourth......

04.03.26 - 15:03	LEVI & KORSINSKY, LLP: INO SHARES DECLINE 24% AS FDA REVIEW CLASSIFICATION REVEALS ALLEGED REGULATORY SETBACK (PR Newswire)
	Alert: Claims Focus on Alleged Misrepresentations About Regulatory Pathway Eligibility NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities of a pending securities class action. Investors have until April......

04.03.26 - 14:54	Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) (PR Newswire)
	Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer Novel combination therapy will be studied as part of the Phase II adaptive......

04.03.26 - 14:06	INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) (PR Newswire)
	Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive form of brain cancer Novel combination therapy will be studied as part of the Phase 2 adaptive......

03.03.26 - 22:36	INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, March 3, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Inovio Pharmaceuticals, Inc. (NASDAQ: INO) between October 10, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 7, 2026......

02.03.26 - 18:03	Inovio Pharmaceuticals, Inc. (INO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit (PR Newswire)
	LOS ANGELES, March 2, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Inovio Pharmaceuticals, Inc. ("Inovio" or the "Company") (NASDAQ: INO). IF YOU SUFFERED A LOSS ON......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Quid sit futurum cras, fuge quaerere! - Forsche nicht danach, was morgen sein wird! - Quintus Flaccus Horaz

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram